UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

~~Form~~FORM 6-K

Report of Foreign Private Issuer

Pursuant to Rule 13a-16 or 15d-16

~~under~~Under the Securities Exchange Act of 1934

For the ~~month~~Month of ~~October~~December 2025 ~~(Report No. 2)~~

001-41502 (Commission File Number~~: 001-41502~~)

WEARABLE DEVICES ~~Ltd~~LTD.

(~~Translation~~Exact name of ~~registrant’s~~Registrant ~~name~~as ~~into~~specified ~~English~~in its charter)

5 Ha-Tnufa Street

Yokne-am Illit, Israel 2066736

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒ Form 40-F ☐

CONTENTS

On October 29, 2025, Wearable Devices Ltd. (the “Company”) entered into a Securities Purchase Agreement (the “Purchase Agreement”) with a single institutional investor (the “Purchaser”), pursuant to which the Company agreed to issue and sell, in a registered direct offering by the Company directly to the Purchaser (the “Registered Direct Offering”): (i) 655,000 of the Company’s ordinary shares, no par value per share (the “Ordinary Shares”), at an offering price of $2.67 per share, together with an accompanying Ordinary Warrant ~~(as defined below); and (ii) pre-funded warrants to acquire up to 575,000 Ordinary Shares (the “Pre-Funded~~Inducement ~~Warrants”) at an offering price of $2.6699 per Pre-Funded Warrant, together with an accompanying Ordinary Warrant.~~Transaction

~~The Pre-Funded Warrants were~~On ~~sold~~November to26, ~~the Purchaser~~2025, ~~whose~~Wearable ~~purchase~~Devices ofLtd. ~~Ordinary Shares in~~ (the ~~Registered~~“Company”) ~~Direct~~entered ~~Offering~~into ~~would~~an ~~otherwise~~inducement ~~have~~offer ~~resulted~~letter inagreement (the ~~Purchaser,~~“Inducement ~~together~~Letter”) with ~~its~~a ~~affiliates~~holder ~~and~~(the ~~certain~~“Holder”) ~~related~~of ~~parties,~~certain ~~beneficially owning more than 9.99%~~ of the ~~outstanding~~Company’s ~~share~~existing ~~capital~~warrants ofto ~~the Company~~purchase ~~following~~up ~~the~~to ~~consummation~~ 3,322,000 of the ~~Registered~~Company’s ~~Direct~~ordinary ~~Offering.~~shares, ~~Each~~no ~~Pre-Funded~~par ~~Warrant~~value ~~represents~~per share (the ~~right~~“Ordinary toShares”), ~~purchase~~issued ~~one~~on ~~Ordinary Share~~August 7, 2025, at an exercise price of $01.~~0001~~71 per ~~share.~~Ordinary ~~The~~Share ~~Pre-Funded Warrants are exercisable immediately and may be exercised at any time until the Pre-Funded Warrants are exercised in full~~ (~~subject to~~ the ~~beneficial~~“Existing ~~ownership limitation described above~~Warrants”).

~~The~~Pursuant to ~~Purchase~~the ~~Agreement~~Inducement ~~contains customary representations~~Letter, ~~warranties~~the ~~and~~Holder ~~agreements~~agreed byto exercise for cash its Existing Warrants, in consideration of the Company,’s ~~customary~~agreement to ~~conditions~~issue new warrants (the “New Warrants”) to ~~closing~~purchase up to 5,813,500 ~~indemnification~~Ordinary ~~obligations~~Shares (the “New Warrant Shares”). The New Warrants will have an exercise price of $1.86 per share, will be initially exercisable on the date that shareholder approval of the issuance of the New Warrants is obtained (the “Shareholder Approval”), and will expire five years following the Shareholder Approval. The Company expects to receive aggregate gross proceeds of approximately $5.68 million from the exercise of the Existing Warrants by the Holder, before deducting fees and other ~~obligations~~expenses payable by the Company. The Company intends to use the net proceeds from the exercise of the ~~parties,~~Existing Warrants for working capital and ~~termination~~other ~~provisions~~general corporate purposes.

~~In addition, unless~~The ~~waived by the Purchaser, the~~ Company ~~agreed~~has ~~that~~engaged ~~for~~A.G.P./Alliance aGlobal ~~period~~Partners ~~of sixty~~ (~~60) days from~~ the ~~closing~~“Financial ~~date of the Registered Direct Offering, it will not: (i~~Advisor”) ~~issue, enter into any agreement~~ to ~~issue~~render orfinancial ~~announce~~services ~~the~~in ~~issuance~~connection ~~or proposed issuance of any Ordinary~~with ~~Shares or equivalent securities; or (ii) file any registration statement or amendment or supplement thereto, other than (a)~~ the ~~Prospectus~~ ~~Supplement~~transactions ~~(as~~contemplated ~~defined~~by ~~below), (b) registration statement on Form S-8, (c)~~ the ~~resale~~Inducement ~~registration~~Letter ~~statement~~and tohas beagreed ~~filed pursuant~~ to ~~the~~pay ~~Company’s obligations under~~ the ~~Securities~~Financial ~~Purchase~~Advisor ~~Agreement~~a ~~dated~~cash ~~September~~fee ~~11,~~equal ~~2025, and the Securities Purchase agreement dated September 12, 2025 (d) any amendment~~ to, or8.0% ~~a new filing~~ of, ~~a registration statement on Form F-3, including for~~ the ~~purposes of selling Ordinary Shares in the ATM Facility (as the term is defined in the Purchase Agreement), (e)~~aggregate ~~any~~gross ~~amendment~~proceeds orreceived ~~supplement~~from ~~to any registration statement that~~ the ~~Company~~Holder’s ~~currently~~exercise ~~has on file on EDGAR and which has been declared effective prior to the date~~ of the ~~Purchase~~Existing ~~Agreement or (f) in connection with the registration for resale of the ordinary shares underlying the Ordinary~~ Warrants ~~issued in the concurrent private placement, as described below)~~. In addition, ~~unless waived by~~ the ~~Purchaser,~~Company ~~the~~has ~~Company~~also agreed ~~that~~to itpay ~~will not conduct any sales of Ordinary Shares or equivalent securities involving a~~the ~~variable~~Financial ~~rate~~Advisor ~~transaction~~up ~~(as~~to ~~defined~~$25,000 ~~in the Purchase Agreement)~~ for alegal ~~period of sixty (60) days, subject to certain exceptions as described in the Purchase Agreement~~fees.

The ~~Ordinary Shares and Pre-Funded~~ ~~Warrants~~closing ~~were~~of ~~offered by~~ the ~~Company~~transactions contemplated pursuant to athe ~~registration~~Inducement ~~statement~~Letter onis ~~Form~~expected ~~F-3~~to ~~(File~~occur ~~No.~~on ~~333-274841)~~or ~~(the~~about ~~“Registration~~December ~~Statement”)~~1, ~~previously~~ ~~filed~~2025 ~~and declared effective by the Securities and Exchange Commission~~ (the “~~Commission~~Closing Date”) ~~on October 18~~, ~~2023, the~~subject ~~base~~to ~~prospectus~~satisfaction ~~filed as part~~ of ~~the~~customary ~~Registration~~closing ~~Statement, and the prospectus supplement dated October 29, 2025 (the “Prospectus Supplement”)~~conditions.

~~In a concurrent private placement~~The ~~(together~~resale with the Registered Direct Offering, the “Offering”), pursuant to the Purchase Agreement, the Company agreed to issue and sell to the Purchaser ordinary warrants to acquire up to 1,230,000 Ordinary Shares (the “Ordinary Warrants” and, together with the Ordinary Shares and the Pre-Funded Warrants, the “Securities”) at an exercise price of ~~$2.67 per share. The Ordinary Warrants will be exercisable immediately upon shareholder approval of~~ the ~~issuance of the~~ Ordinary ~~Warrants is obtained and will expire five years from the date shareholder approval is obtained. The Ordinary Warrants and the Ordinary~~ Shares ~~issuable~~underlying ~~upon~~ the ~~exercise~~ ofExisting ~~the Ordinary~~ Warrants ~~are~~have ~~not~~been ~~being~~ registered ~~under the Securities Act of 1933, as amended (the “Securities Act”), were not offered~~ pursuant to ~~the~~an ~~Registration~~existing Statement and Prospectus Supplement and were offered pursuant to the exemption provided in Section 4(a)(2) under the Securities Act and/or Regulation D promulgated thereunder. The Purchase Agreement requires the Company to file a registration statement on Form F-3 (orFile ~~any~~No. ~~other available form~~333-291100), asdeclared ~~soon~~effective asby ~~practicable (and in any event within 15 calendar days of~~ the ~~date~~Securities ~~of the shareholder approval), to register the Ordinary Shares issuable upon exercise of the Ordinary Warrants~~ and toExchange use commercially reasonable efforts to cause such registration statement to become effective within 60 days, or within 90 days of the filing of the registration statement in the event of a full review by the Commission, ~~with a limited extension of~~ (the ~~effectiveness~~“SEC”) ~~date~~on toNovember ~~take into account the current shutdown of certain departments and agencies of the U.S. government~~24, ~~and to keep such registration statement effective as provided in the Purchase Agreement~~2025.

InThe Company ~~connection~~also ~~with~~agreed ~~the~~to ~~Offering,~~ file a registration statement on Form F-1 or Form F-3 to register the ~~Company~~resale ~~also~~of ~~entered~~the ~~into~~New anWarrant ~~agreement~~Shares. The Company committed to ~~amend~~file ~~existing~~such ~~warrants~~registration statement (the ~~“Warrant~~Resale ~~Amendment~~Registration ~~Agreement~~Statement”) ~~that~~within ~~were~~30 ~~previously~~calendar days of the date ~~issued~~of inShareholder ~~September~~Approval, ~~2025~~to use commercially reasonable efforts to ~~the~~cause ~~investor~~it ~~participating~~to become effective within 60 calendar days of such date (or 90 days in case of a review by the ~~Offering~~SEC), and to keep it effective at all times until no holder of the New Warrants owns any New Warrants or New Warrant Shares. ~~Such~~The ~~existing~~Company ~~warrants~~may ~~originally~~satisfy ~~entitled~~its obligations under the ~~investor~~Inducement toLetter ~~purchase~~and under the Securities upPurchase toAgreement, ~~(i)~~dated 1October 29,~~000~~ 2025,~~000~~ ~~ordinary~~by ~~shares~~and ofbetween the Company, ~~with~~and anthe ~~exercise~~holder ~~price~~ of ~~$4.00~~the ~~per~~Existing ~~share~~Warrants and upNew toWarrants (iithe “October SPA”) ~~670,000~~by ~~ordinary~~filing ~~shares~~a ~~of the Company~~single, ~~with~~combined anregistration ~~exercise~~statement ~~price~~covering ofboth ~~$6.00~~the ~~per~~New ~~share.~~Warrant ~~Such~~Shares ~~existing~~and ~~warrants~~the securities ~~have~~required ~~been~~to ~~amended~~be toregistered ~~reduce~~under the ~~exercise~~October ~~price~~SPA towithin ~~$2.67 per~~such ~~share~~time frame. The ~~warrant~~Company ~~amendment~~also isagreed ~~also~~not ~~subject~~to effect or agree to effect ~~shareholder~~any ~~approval,~~Variable ~~and~~Rate Transaction (as defined in the ~~warrants~~Inducement ~~shall~~Letter) ~~expire~~for ~~five~~a ~~years~~period ~~from~~of 30 days after the date ~~shareholder~~of the Inducement ~~approval~~Letter is(subject ~~obtained~~to certain exceptions).

The New Warrants and the New Warrant Shares are being offered and sold pursuant to an exemption from the registration requirements under Section 4(a)(2) of the Securities Act of 1933, as amended (the “Securities Act”). The Holder has represented that it is an accredited investor as defined in Rule 501 of the Securities Act and has acquired such securities for its own account and has no arrangements or understandings for any distribution thereof. The offer and sale of the New Warrants and New Warrant Shares is being made without any form of general solicitation or advertising. The New Warrants and the New Warrant Shares have not been registered under the Securities Act or applicable state securities laws. Accordingly, the New Warrants and New Warrant Shares may not be offered or sold in the United States except pursuant to an effective registration statement or an applicable exemption from the registration requirements of the Securities Act and such applicable state securities laws.

This Report of Foreign Private Issuer on Form 6-K (this “Form 6-K”) shall not constitute an offer to sell or the solicitation to buy nor shall there be any sale of the securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

~~The~~Terms ~~foregoing summaries~~ of ~~the~~ ~~Purchase Agreement,~~ the ~~Ordinary~~New Warrants, the Pre-Funded Warrants, and the Warrant Amendment Agreement do not purport to be complete and are subject to, and qualified in their entirety by, such documents filed as Exhibits 10.1, 4.1, 4.2, and 4.3, respectively, hereto and incorporated by reference herein. A copy of the press release related to the Offering entitled “Wearable Devices Announces Pricing of $3.3 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market Under Nasdaq Rules” is furnished as Exhibit 99.1 hereto and is incorporated by reference herein.

~~This~~The following ~~Report~~summary of ~~Foreign~~certain ~~Private Issuer~~terms onand ~~Form~~provisions ~~6-K~~of ~~(this~~the ~~“Form~~New ~~6-K”)~~Warrants ~~shall~~is not ~~constitute~~complete anand ~~offer~~is subject to, ~~sell~~and ~~any~~qualified ~~securities~~in orits ~~a solicitation of an offer to~~entirety ~~buy any securities~~by, ~~nor~~the ~~shall~~provisions ~~there be any sale~~ of ~~any~~the ~~securities~~New inWarrants, ~~any~~the ~~state~~form orof ~~jurisdiction in~~ which ~~such~~is anfiled ~~offer,~~as ~~solicitation~~Exhibit ~~or sale~~4.1 ~~would be unlawful prior~~ to ~~registration~~this orForm ~~qualification~~6-K ~~under~~and ~~the~~is ~~securities~~incorporated ~~laws~~herein ofby ~~any such state or jurisdiction~~reference.

~~Copies of the opinions of~~Issuance, ~~Sullivan~~Duration ~~& Worcester Tel Aviv (Har-Even & Co.)~~ and ~~Sullivan~~Exercise ~~& Worcester LLP relating to the legality of the issuance and sale of the Ordinary Shares and the Pre-Funded Warrants, respectively, are filed as Exhibits 5.1 and 5.2 hereto, respectively.~~Price

~~This~~The ~~Report~~issuance isof ~~incorporated~~the New Warrants byand ~~reference~~the ~~into~~New Warrant Shares are subject to the ~~registration~~Shareholder ~~statements~~Approval. onEach ~~Form~~New ~~S-8~~Warrant ~~(File~~will ~~Nos~~have an exercise price equal to $1.86 ~~333-290148,~~per Ordinary ~~333-284010,~~Share. ~~333-269869~~The New Warrants will be immediately exercisable on the date of Shareholder Approval (the “Initial Exercise Date”) and ~~333-274343)~~will ~~and~~expire on ~~Form~~the Ffive-~~3 (File~~year ~~Nos~~anniversary of the Initial Exercise Date. ~~333-274841,333-287247~~The Company shall hold an annual or special meeting of shareholders ~~and~~on ~~333-291100)~~or prior to the date that is 90 days following the Closing Date for the purpose of obtaining the Shareholder Approval. If the Company, does ~~filed~~not ~~with~~obtain Shareholder Approval at the ~~Commission~~first meeting, tothe beCompany shall call a ~~part~~meeting ~~thereof~~every ~~from~~90 days thereafter to seek Shareholder Approval until the earlier of the date on which ~~this~~Shareholder ~~report~~Approval is ~~submitted,~~obtained or the New Warrants are no longer outstanding. The exercise price and the number of Ordinary Shares issuable upon exercise of the New Warrants are subject to adjustment in the event of share dividends, ~~extent~~share ~~not~~splits, ~~superseded~~subsequent byrights ~~documents~~offerings, pro rata distributions, reorganizations, or ~~reports~~similar ~~subsequently~~events ~~filed~~affecting the Ordinary Shares or the ~~furnished~~exercise price.

~~Forward-Looking Statements:~~Exercisability

~~This Report contains forward-looking~~The ~~statements~~New ~~within~~Warrants ~~the~~will ~~meaning~~be ofexercisable ~~the~~at ~~“safe~~any ~~harbor”~~time ~~provisions~~on ofor after the ~~Private~~Initial ~~Securities~~Exercise ~~Litigation Reform Act of 1995 and other federal securities laws. For example~~Date, ~~the~~at ~~Company is using forward-looking statements when it discusses~~ the ~~closing~~option of ~~the~~each ~~Offering and~~holder, ~~issuance~~in ofwhole ~~warrants~~or ~~that~~in ~~are~~part, by ~~subject~~delivering to ~~shareholder~~us ~~approvals.~~a ~~The~~duly ~~Offering~~executed isexercise ~~subject~~notice toaccompanied ~~closing~~by ~~conditions~~payment ~~and~~in ~~the~~full ~~Company’s shareholders~~for ~~may not approve~~ the ~~warrants~~number ~~that~~of ~~require~~Ordinary ~~shareholder~~Shares ~~approval.~~purchased ~~All~~upon ~~statements~~such exercise ~~other~~(except ~~than~~in ~~statements~~the case of ~~historical~~a ~~facts included~~cashless inexercise ~~this~~as ~~Report~~discussed ~~are forward-looking statements~~below). ~~Forward-looking~~A ~~statements~~holder ~~are~~(together ~~neither~~with ~~historical~~its ~~facts~~affiliates) ~~nor~~may ~~assurances~~not ofexercise ~~future~~any ~~performance.~~portion ~~Instead,~~of ~~they~~such ~~are based only on the Company~~holder’s ~~current~~New ~~beliefs,~~Warrants ~~expectations~~to ~~and~~the ~~assumptions~~extent ~~regarding~~that the ~~future~~holder ~~of its~~would ~~business,~~own ~~future~~more ~~plans~~than ~~and~~4.99% ~~strategies~~(or, ~~projections,~~at ~~anticipated events and trends,~~ the ~~economy~~election ~~and~~of ~~other future conditions. Because forward-looking statements relate to~~ the ~~future~~holder, ~~they are subject to inherent uncertainties, risks and changes in circumstances that are~~ ~~difficult~~9.99%) ~~to predict and many~~ of ~~which are outside of~~ the Company’s ~~control.~~outstanding ~~The~~Ordinary ~~Company’s~~Shares ~~actual~~immediately ~~results~~after ~~and~~exercise, ~~financial~~except ~~condition may~~that ~~differ~~upon ~~materially~~prior notice from ~~those~~the ~~indicated~~holder into us, the ~~forward-looking~~holder ~~statements.~~may ~~Therefore,~~increase ~~you~~or ~~should~~decrease ~~not~~the ~~rely~~amount onof ~~any~~ownership of ~~these~~outstanding ~~forward-looking statements.~~Ordinary ~~Important~~Shares ~~factors~~after ~~that~~exercising ~~could~~the ~~cause~~holder’s ~~our~~New Warrants ~~actual~~up ~~results and financial condition~~ to ~~differ~~9.99% ~~materially~~of ~~from those indicated in~~ the ~~forward-looking~~number ~~statements~~of ~~include~~ the ~~risks and uncertainties described in the~~ Company’s ~~annual~~Ordinary ~~report~~Shares onoutstanding ~~Form~~immediately ~~20-F~~after ~~for~~giving ~~the year~~effect ~~ended~~to ~~December~~the 31exercise, as ~~2024,~~such ~~filed~~percentage ~~with~~ownership ~~the~~is ~~Commission~~determined onin ~~March~~accordance ~~20,~~with ~~2025, and~~ the ~~Company’s~~terms ~~other~~of ~~filings with~~ the ~~Commission~~New Warrants. ~~The~~ ~~Company undertakes no obligation to publicly update any forward-looking statement~~Furthermore, ~~whether~~the ~~written~~holder orwill ~~oral,~~not ~~that~~exceed ~~may be made from~~beneficial ~~time~~ownership ~~to time, whether as a result~~ of ~~new~~24.99% ~~information,~~at ~~future~~any ~~developments or otherwise~~time.

Cashless Exercise

If, at the time after the six month anniversary of the date of issuance a registration statement registering the resale of the New Warrant Shares by the holder under the Securities Act is not then effective or available, then in lieu of making the cash payment otherwise contemplated to be made to the Company upon such exercise in payment of the aggregate exercise price, the holder may elect instead to receive upon such exercise (either in whole or in part), the net number of Ordinary Shares determined according to a formula set forth in the New Warrants.

Trading Market

There is no established trading market for the New Warrants, and the Company does not expect an active trading market to develop. The Company does not intend to apply to list the New Warrants on any securities exchange or other trading market. Without a trading market, the liquidity of the New Warrants will be extremely limited.

Rights as a Shareholder

Except as otherwise provided in the New Warrants or by virtue of the holder’s ownership of the Company’s Ordinary Shares, such holder of New Warrants does not have the rights or privileges of a holder of the Company’s Ordinary Shares, including any voting rights, until such holder exercises such holder’s New Warrants. The New Warrants will provide that the holders of the New Warrants have the right to participate in distributions or dividends paid on the Company’s Ordinary Shares.

Fundamental Transactions

If, at any time while the New Warrants are outstanding, the Company, either directly or indirectly, effects a Fundamental Transaction (as defined in the New Warrants), each holder will have the right to receive, upon exercise of the New Warrants, the same amount and kind of securities, cash, or other property that the holder would have received had the holder exercised the New Warrants immediately prior to the Fundamental Transaction. In addition, in certain cases, and at the holder’s option, the Company may be required to repurchase the unexercised portion of the New Warrants from the holder for cash equal to the Black Scholes Value (as defined in the New Warrants) of such portion, subject to the terms and conditions set forth in the New Warrants.

~~EXHIBIT~~Waivers and ~~INDEX~~Amendments

Exhibit No.		Description
4.1		Form of Ordinary Warrant.
4.2		Form of Pre-Funded Warrant.
4.3		Form of Warrant Amendment Agreement
5.1		Opinion of Sullivan & Worcester Tel Aviv (Har-Even & Co.)
5.2		Opinion of Sullivan & Worcester LLP
10.1		Form of Securities Purchase Agreement, dated as of October 29, 2025, by and between the Company and the purchaser party thereto.
23.1		Consent of Sullivan & Worcester Tel Aviv (Har-Even & Co.) (included in Exhibit 5.1).
23.2		Consent of Sullivan & Worcester LLP (included in Exhibit 5.2).
99.1		Press Release issued by Wearable Devices Ltd., dated October 30, 2025, titled “Wearable Devices Announces Pricing of $3.3 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market Under Nasdaq Rules.”

The New Warrants may be modified or amended or the provisions of the New Warrants waived with the Company’s and the holder’s written consent.

The forms of Inducement Letter and the New Warrant are attached as Exhibits 10.1 and 4.1, respectively. The description of the terms of the Inducement Letter and the New Warrants are not intended to be complete and are qualified in its entirety by reference to such exhibits. The Inducement Letter contains customary representations, warranties and covenants by us which were made only for the purposes of such agreements and as of specific dates, were solely for the benefit of the parties to such agreements and may be subject to limitations agreed upon by the contracting parties.

Press Release

On November 28, 2025, the Company issued a press release titled “Wearable Devices Ltd. Announces a Warrant Inducement Transaction for $5.68 Million in Gross Proceeds,” a copy of which is furnished as Exhibit 99.1 with this Form 6-K.

Option Pool Increase

On November 26, 2025, the Board of Directors of the Company approved an increase in the number of Ordinary Shares of the Company reserved for issuance under the Company’s 2024 Global Equity Incentive Plan by 1,678,604 from 795,252 to 2,473,856.

Forward-Looking Statements

This Form 6-K contains forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995 and other Federal securities laws. For example, the Company is using forward-looking statements when it discusses the expected closing of the transactions contemplated by the Inducement Letter, the use of proceeds, and the satisfaction of customary closing conditions. All statements other than statements of historical facts included in this Form 6-K are forward-looking statements. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on the Company’s current beliefs, expectations and assumptions regarding the future of its business, future plans and strategies, projections, anticipated events and trends, the economy and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of the Company’s control. The Company’s actual results and financial condition may differ materially from those indicated in the forward-looking statements. Therefore, you should not rely on any of these forward-looking statements. Important factors that could cause the Company’s actual results and financial condition to differ materially from those indicated in the forward-looking statements include among others, the following: the trading of its ordinary shares or warrants and the development of a liquid trading market; the Company’s ability to successfully market its products and services; the acceptance of the Company’s products and services by customers; the Company’s continued ability to pay operating costs and ability to meet demand for its products and services; the amount and nature of competition from other security and telecom products and services; the effects of changes in the cybersecurity and telecom markets; the Company’s ability to successfully develop new products and services; the Company’s success establishing and maintaining collaborative, strategic alliance agreements, licensing and supplier arrangements; the Company’s ability to comply with applicable regulations; and other risks and uncertainties described in the Company’s annual report on Form 20-F for the year ended December 31, 2024, filed with the SEC on March 20, 2025. The Company undertakes no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.

This Form 6-K and the press release attached hereto as Exhibit 99.1 are incorporated by reference into the registration statements on Form S-8 (File Nos. 333-290148, 333-284010, 333-269869, and 333-274343) and on Form F-3 (File Nos. 333-274841, 333-287247 and 333-291100) of the Company, filed with the SEC, to be a part thereof from the date on which this 6-K is submitted, to the extent not superseded by documents or reports subsequently filed or furnished.

Exhibit Index

Exhibit No.		Description
4.1		Form of New Warrant
10.1		Form of Inducement Letter
99.1		Press Release issued by Wearable Devices Ltd. dated November 28, 2025, titled “Wearable Devices Ltd. Announces a Warrant Inducement Transaction for $5.68 Million in Gross Proceeds.”

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	Wearable Devices Ltd.
Date: December 1, 2025	By:	/s/ Asher Dahan
Date: October 31, 2025	By:	/s/ Asher Dahan
		Asher Dahan
		Chief Executive Officer

Filing Compare · Wearable Devices Ltd.